Pharmanovia Benelux
Have updates for this profile? Please contribute data
= Subscriber Access Only
You are viewing a preview of this profile. Request a Preqin Pro demo for full access to all profiles and underlying data.
With Preqin Pro, you gain an unobstructed view of all alternative asset class activity across institutional investors, fund managers, funds, portfolio companies, deals, exits, and service providers.
Pharmanovia Benelux - overview
Established
2013
Location
-, -, UK
Primary Industry
Pharmaceuticals
About
Pharmanovia, formerly known as Atnahs Pharma, operates in the UK, specializing in life cycle management of established medicines, ensuring enhanced patient outcomes through innovative pharmaceutical solutions. Founded in 2013 and headquartered in the UK, Pharmanovia focuses on the life cycle management of established medicines. The company has engaged in two significant deals, with the most recent occurring on August 8, 2024. The current CEO is James Burt, who has experience in the pharmaceutical sector, although further details about the founder’s history were not provided.
Pharmanovia specializes in life cycle management of established medicines, enhancing patient outcomes through innovative solutions. Its offerings span various therapeutic areas, including cardiovascular, endocrinology, neurology, and oncology. Notable products include Inderal®, Tenormin®, Anaprox®, Bonviva®, and Synacthen®, which address health conditions from hypertension to osteoporosis. The company utilizes patient and clinician insights to meet market needs and operates across diverse regions, including Europe and Eastern Europe, serving healthcare providers, pharmacies, and distributors.
In the most recent fiscal year 2024, Pharmanovia reported revenue of EUR 509. 84 mn and an EBITDA of EUR 180. 05 mn. The company's revenue is generated through partnerships and direct transactions with healthcare providers and distributors, following a B2B model, with flagship products like Zestril® and Valium® contributing significantly to its income.
Pharmanovia is focused on launching new products designed to meet specific health challenges. Recent funding, including a EUR 5 million senior term loan from CIC Private Debt received on August 8, 2024, will be utilized to support these product initiatives. The company is also looking to expand into new geographical markets, although specific regions and timelines for this expansion were not detailed.
Current Investors
Triton
Primary Industry
Pharmaceuticals
Sub Industries
Specialty Pharmaceuticals, Pharmaceutical Research & Development
Website
www.atnahs.com
Verticals
Manufacturing
Company Stage
Mature - Buyout
Total Amount Raised
Subscriber access only
Pharmanovia Benelux - timeline of key events
Pharmanovia Benelux - financials
| Fiscal Year Ended | Mar 31, 2014 | Mar 31, 2015 | Mar 31, 2016 | Mar 31, 2017 | Mar 31, 2018 | Mar 31, 2019 | Mar 31, 2020 | Mar 31, 2021 | Mar 31, 2022 | Mar 31, 2023 | Mar 31, 2024 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue (USD) | 1,755,000 | 10,854,000 | 38,790,000 | 51,846,000 | 107,033,000 | 118,092,000 | 141,741,000 | 226,084,000 | - | - | - |
| % Revenue Growth (YoY) | - | 518.5% | 257.4% | 33.7% | 106.4% | 10.3% | 20.0% | 59.5% | - | - | - |
| EBITDA (USD) | 70,000 | 5,214,000 | 17,437,000 | 29,399,000 | 62,201,000 | 59,383,000 | 60,463,000 | 101,064,000 | - | - | - |
| Operating Income (USD) | (467,000) | 1,583,000 | 7,499,000 | 17,271,000 | 28,457,000 | 18,928,000 | 11,754,000 | 15,358,000 | - | - | - |
| Operating Margin | (26.6%) | 14.6% | 19.3% | 33.3% | 26.6% | 16.0% | 8.3% | 6.8% | - | - | - |
| % EBITDA Margin | 4.0% | 48.0% | 45.0% | 56.7% | 58.1% | 50.3% | 42.7% | 44.7% | - | - | - |
| NET Income (USD) | (659,000) | 318,000 | 2,897,000 | 11,119,000 | 19,106,000 | 9,585,000 | (2,145,000) | (6,955,000) | - | - | - |
| % Net Margin | (37.5%) | 2.9% | 7.5% | 21.4% | 17.9% | 8.1% | (1.5%) | (3.1%) | - | - | - |
Pharmanovia Benelux - deals
| Deals Type | Deal Status | Target (s) | Deal Date | Investor(s) | Seller(s) | Deal size (Mn) | Enterprise value (Mn) | Post-money valuation (Mn) | EBITDA multiple (x) | Revenue multiple (x) | Lead partner (s) |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Private Debt | Completed | Pharmanovia Benelux | - | ||||||||
| Add-on | Completed | Lamepro BV | - | ||||||||
| Add-on | Completed | AstraZeneca's Cardiovascular Medicine | - | ||||||||
| Buyout | Completed | Pharmanovia Benelux | - |
Displaying 1 - 4 of 4
Pharmanovia Benelux - employee data
Time to go Pro
Get Preqin Pro for unrestricted access to 600,000+ detailed profiles on fund managers, investors, funds, companies, and other alternative asset players. Unlock exclusive data on future plans, company financials, fundraising history, track records, and more.